{
  "index": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28
  ],
  "columns": [
    "section_level",
    "CPT_section",
    "type",
    "content",
    "font_info",
    "level_1_CPT_section",
    "file_section",
    "file_section_num",
    "file_section_level",
    "seq_num"
  ],
  "data": [
    [
      "",
      "Unmapped",
      "text",
      "<b>Clinical Study Protocol</b>",
      "{'IsBold': True, 'font_size': 20, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      1.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study Intervention  Capivasertib (AZD5363)",
      "{'IsBold': False, 'font_size': 20, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      3.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Study Code D361BC00001",
      "{'IsBold': False, 'font_size': 20, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      7.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Version 1.0",
      "{'IsBold': False, 'font_size': 20, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      11.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Date 03 March 2020",
      "{'IsBold': False, 'font_size': 20, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      15.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b>---------------------</b>",
      "",
      "",
      "TITLE",
      "",
      1,
      ""
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b>A Phase III Double-Blind, Randomised, Placebo-Controlled Study\nAssessing the Efficacy and Safety of Capivasertib + Abiraterone<\nVersus Placebo + Abiraterone as Treatment for Patients with De\nNovo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)\nCharacterised by PTEN deficiency (CAPItello-281)</b>",
      "{'IsBold': True, 'font_size': 32, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      18.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b>---------------------</b>",
      "",
      "Unmapped",
      "TITLE",
      "",
      1,
      ""
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b> Sponsor Name: AstraZeneca</b>",
      "{'IsBold': False, 'font_size': 24, 'font_style': 'Heading1'}",
      "Unmapped",
      "TITLE",
      "",
      1,
      23.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Legal Registered Address:",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      24.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "AstraZeneca AB, 151 85 S\u00f6dert\u00e4lje, Sweden",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      25.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "AstraZeneca K.K., 3-1, Ofuka-cho, Kita-ku, Osaka 530-0011, Japan",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      26.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b> Regulatory Agency Identifier Number(s)</b>",
      "{'IsBold': False, 'font_size': 24, 'font_style': 'Heading1'}",
      "Unmapped",
      "TITLE",
      "",
      1,
      27.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "EudraCT Number: 2020-000346-33",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      28.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "IND Number: 113139",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      29.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "This Clinical Study Protocol has been subject to a peer review according to AstraZeneca Standard procedures. The Clinical Study Protocol is publicly registered and the results are disclosed and/or published according to the AstraZeneca Global Policy on Bioethics and in compliance with prevailing laws and regulations.",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      30.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "<b> Protocol Number:</b> D361BC00001",
      "{'IsBold': False, 'font_size': 24, 'font_style': 'Heading1'}",
      "Unmapped",
      "TITLE",
      "",
      1,
      32.0
    ],
    [
      "",
      "Unmapped",
      "text",
      "Amendment Number: Not Applicable",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Unmapped",
      "TITLE",
      "",
      1,
      33.0
    ],
    [
      1.0,
      "Protocol Summary",
      "header",
      "<h1> 1  PROTOCOL SUMMARY </h1>",
      "{'IsBold': False, 'font_size': -1, 'font_style': 'Heading1'}",
      "Protocol Summary",
      "PROTOCOL SUMMARY",
      1.0,
      1,
      192.0
    ],
    [
      2.0,
      "Synopsis",
      "header",
      "<h2> 1.1  Synopsis </h2>",
      "{'IsBold': False, 'font_size': 28, 'font_style': 'Heading2'}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      193.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "<b>Protocol Title:</b> A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as\nTreatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)\n",
      "{'IsBold': True, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      194.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "<b>Short Title:</b>Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN deficiency.",
      "{'IsBold': True, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      197.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "<b>Rationale:</b>",
      "{'IsBold': True, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      199.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "There is an important unmet medical need for treatments in the de novo mHSPC setting that are able to delay cancer progression and ultimately, death, particularly in patients whose tumours are characterised by PTEN deficiency.Available nonclinical and clinical evidence suggests that the combined inhibition of serine/threonine specific protein kinase (AKT) and the androgen receptor (AR) axis may improve treatment outcomes in mHSPC.The purpose of this study is to determine the efficacy and safety of the combination of the AKT inhibitor capivasertib and the androgen biosynthesis inhibitor abiraterone combined with a steroid, given on a background of androgen deprivation therapy (ADT) in patients with newly diagnosed, previously untreated mHSPC and PTEN-deficient tumours.",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      200.0
    ],
    [
      2.0,
      "Synopsis",
      "header",
      "<h3> Objectives and Endpoints</h3>",
      "{'IsBold': False, 'font_size': 24, 'font_style': 'Heading3'}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      203.0
    ],
    [
      2.0,
      "Synopsis",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\\n  <thead>\\n    <tr style=\"text-align: right;\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td>Objectives</td>\\n      <td>Endpoints</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>Primary</td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of radiographic progression-free survival (rPFS) in patients with PTEN-deficient mHSPC.</td>\\n      <td>\u2022  rPFS is defined as the time from randomisation to: 1) radiographic progression, as assessed by the investigator per RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), or 2) death due to any cause.</td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>Key Secondary</td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of overall survival.</td>\\n      <td>\u2022  Overall survival is the length of time from randomisation until the date of death due to any cause.</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of time to start of first subsequent therapy or death (TFST).</td>\\n      <td>\u2022  TFST is defined as time from randomisation to the earlier of: the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment (capivasertib/placebo), or death due to any cause.</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of symptomatic skeletal event-free survival (SSE-FS).</td>\\n      <td>\u2022  SSE-FS is defined as time from randomisation until any of the following:</td>\\n    </tr>\\n  </tbody>\\n</table>",
        "TableIndex": "4",
        "TableName": "Objectives and Endpoints",
        "Header": [0]
      },
      "{'IsBold': True, 'font_size': 22, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      204.0
    ],
    [
      2.0,
      "Synopsis",
      "table",
      {
        "Table": "<table border=\"1\" class=\"dataframe\">\\n  <thead>\\n    <tr style=\"text-align: right;\">\\n      <th>ColIndex</th>\\n      <th>1.0</th>\\n      <th>2.0</th>\\n      <th>3.0</th>\\n      <th>4.0</th>\\n    </tr>\\n  </thead>\\n  <tbody>\\n    <tr>\\n      <th>0</th>\\n      <td></td>\\n      <td>Use of radiation therapy to prevent or relieve skeletal symptoms.   Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). Radiologic documentation is required. A pathological fracture, as determined by investigator, is defined as associated with low or no trauma and deemed to have occurred at a site of bone metastasis.  Occurrence of spinal cord compression. Radiologic documentation is required.  Orthopaedic surgical intervention for bone metastasis.   Death due to any cause.</td>\\n      <td>Use of radiation therapy to prevent or relieve skeletal symptoms.   Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). Radiologic documentation is required. A pathological fracture, as determined by investigator, is defined as associated with low or no trauma and deemed to have occurred at a site of bone metastasis.  Occurrence of spinal cord compression. Radiologic documentation is required.  Orthopaedic surgical intervention for bone metastasis.   Death due to any cause.</td>\\n      <td>Use of radiation therapy to prevent or relieve skeletal symptoms.   Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral). Radiologic documentation is required. A pathological fracture, as determined by investigator, is defined as associated with low or no trauma and deemed to have occurred at a site of bone metastasis.  Occurrence of spinal cord compression. Radiologic documentation is required.  Orthopaedic surgical intervention for bone metastasis.   Death due to any cause.</td>\\n    </tr>\\n    <tr>\\n      <th>1</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of time to pain progression (TTPP).</td>\\n      <td>\u2022  TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 \u2018worst pain in 24 hours\u2019 score and/or initiation of/increase in opiate analgesic use.</td>\\n      <td>\u2022  TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 \u2018worst pain in 24 hours\u2019 score and/or initiation of/increase in opiate analgesic use.</td>\\n      <td>\u2022  TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 \u2018worst pain in 24 hours\u2019 score and/or initiation of/increase in opiate analgesic use.</td>\\n    </tr>\\n    <tr>\\n      <th>2</th>\\n      <td>Other Secondary</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>3</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of time to PSA progression.</td>\\n      <td>\u2022  The time from randomisation to PSA progression, as determined by PCWG3 criteria.</td>\\n      <td>\u2022  The time from randomisation to PSA progression, as determined by PCWG3 criteria.</td>\\n      <td>\u2022  The time from randomisation to PSA progression, as determined by PCWG3 criteria.</td>\\n    </tr>\\n    <tr>\\n      <th>4</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of time to castration resistance (TTCR).</td>\\n      <td>\u2022  TTCR is defined as the time from randomisation to the first castration-resistant event (radiographic disease progression, PSA progression, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL).</td>\\n      <td>\u2022  TTCR is defined as the time from randomisation to the first castration-resistant event (radiographic disease progression, PSA progression, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL).</td>\\n      <td>\u2022  TTCR is defined as the time from randomisation to the first castration-resistant event (radiographic disease progression, PSA progression, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL).</td>\\n    </tr>\\n    <tr>\\n      <th>5</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone versus placebo + abiraterone on fatigue intensity (based on worst fatigue item), fatigue severity domain and fatigue interference domain assessed by the Brief Fatigue Inventory (BFI).</td>\\n      <td>BFI endpoints may include: Time to deterioration in fatigue intensity (defined as a change \u2265 2 points from baseline in worst fatigue item [Item 3] score) (TTDF). Time to deterioration in fatigue interference (defined as a change \u2265 1.25 points from baseline in fatigue interference domain score) Change from baseline in fatigue severity and fatigue interference domain scores.</td>\\n      <td>BFI endpoints may include: Time to deterioration in fatigue intensity (defined as a change \u2265 2 points from baseline in worst fatigue item [Item 3] score) (TTDF). Time to deterioration in fatigue interference (defined as a change \u2265 1.25 points from baseline in fatigue interference domain score) Change from baseline in fatigue severity and fatigue interference domain scores.</td>\\n      <td>BFI endpoints may include: Time to deterioration in fatigue intensity (defined as a change \u2265 2 points from baseline in worst fatigue item [Item 3] score) (TTDF). Time to deterioration in fatigue interference (defined as a change \u2265 1.25 points from baseline in fatigue interference domain score) Change from baseline in fatigue severity and fatigue interference domain scores.</td>\\n    </tr>\\n    <tr>\\n      <th>6</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of overall pain severity and pain interference using the BPI-SF questionnaire.</td>\\n      <td>\u2022  BPI-SF: Change from baseline in pain severity and pain interference domain scores.</td>\\n      <td>\u2022  BPI-SF: Change from baseline in pain severity and pain interference domain scores.</td>\\n      <td>\u2022  BPI-SF: Change from baseline in pain severity and pain interference domain scores.</td>\\n    </tr>\\n    <tr>\\n      <th>7</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone versus placebo + abiraterone by assessment of disease related symptoms and HRQoL using the Functional Assessment of Cancer Therapy \u2013 Prostate Cancer (FACT-P) questionnaire.</td>\\n      <td>FACT-P:  1  Time to deterioration in FACT-P scores (FACT-P total score, FACT-G total score, TOI, functional well-being, physical well-being, prostate cancer subscale, and FAPSI-6, respectively).</td>\\n      <td>FACT-P:  1  Time to deterioration in FACT-P scores (FACT-P total score, FACT-G total score, TOI, functional well-being, physical well-being, prostate cancer subscale, and FAPSI-6, respectively).</td>\\n      <td>FACT-P:  1  Time to deterioration in FACT-P scores (FACT-P total score, FACT-G total score, TOI, functional well-being, physical well-being, prostate cancer subscale, and FAPSI-6, respectively).</td>\\n    </tr>\\n    <tr>\\n      <th>8</th>\\n      <td></td>\\n      <td>2</td>\\n      <td>Change from baseline in FACT-P scores (FACT-P total score, FACT-G total score, TOI, functional well-being, physical well-being, prostate cancer subscale, and FAPSI-6, respectively).</td>\\n      <td>Change from baseline in FACT-P scores (FACT-P total score, FACT-G total score, TOI, functional well-being, physical well-being, prostate cancer subscale, and FAPSI-6, respectively).</td>\\n    </tr>\\n    <tr>\\n      <th>9</th>\\n      <td>\u2022  To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of progression-free survival after next-line treatment (PFS2).</td>\\n      <td>\u2022</td>\\n      <td>PFS2 is defined as time from randomisation until progression on next-line treatment, as clinical progression, PSA progression, or radiographic progression determined by RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), as assessed by the investigator, or death due to any cause.</td>\\n      <td>PFS2 is defined as time from randomisation until progression on next-line treatment, as clinical progression, PSA progression, or radiographic progression determined by RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), as assessed by the investigator, or death due to any cause.</td>\\n    </tr>\\n    <tr>\\n      <th>10</th>\\n      <td>\u2022 To evaluate the PK of capivasertib in combination with abiraterone .</td>\\n      <td>\u2022</td>\\n      <td>Plasma concentration of capivasertib pre-dose (C trough ) and post-dose (C 1h and C 4h ).</td>\\n      <td>Plasma concentration of capivasertib pre-dose (C trough ) and post-dose (C 1h and C 4h ).</td>\\n    </tr>\\n    <tr>\\n      <th>11</th>\\n      <td></td>\\n      <td>\u2022</td>\\n      <td>Plasma PK parameters derived from a population PK model, as permitted by the data.</td>\\n      <td>Plasma PK parameters derived from a population PK model, as permitted by the data.</td>\\n    </tr>\\n    <tr>\\n      <th>12</th>\\n      <td>S afety</td>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n    </tr>\\n    <tr>\\n      <th>13</th>\\n      <td>\u2022  To assess the safety and tolerability of capivasertib + abiraterone as compared to placebo + abiraterone in patients with PTEN-deficient mHSPC.</td>\\n      <td>\u2022</td>\\n      <td>Safety and tolerability will be evaluated in terms of AEs/SAEs, vital signs, clinical chemistry/ haematology/glucose metabolism parameters, and ECG parameters.</td>\\n      <td>Safety and tolerability will be evaluated in terms of AEs/SAEs, vital signs, clinical chemistry/ haematology/glucose metabolism parameters, and ECG parameters.</td>\\n    </tr>\\n    <tr>\\n      <th>14</th>\\n      <td></td>\\n      <td>\u2022</td>\\n      <td>Assessments related to AEs cover:  Occurrence/frequency</td>\\n      <td>Assessments related to AEs cover:  Occurrence/frequency</td>\\n    </tr>\\n    <tr>\\n      <th>15</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Relationship to capivasertib and abiraterone as assessed by investigator</td>\\n    </tr>\\n    <tr>\\n      <th>16</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>CTCAE grade</td>\\n    </tr>\\n    <tr>\\n      <th>17</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Seriousness</td>\\n    </tr>\\n    <tr>\\n      <th>18</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Death</td>\\n    </tr>\\n    <tr>\\n      <th>19</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs leading to discontinuation of capivasertib/placebo</td>\\n    </tr>\\n    <tr>\\n      <th>20</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs leading to discontinuation of abiraterone</td>\\n    </tr>\\n    <tr>\\n      <th>21</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs leading to dose interruption of capivasertib/placebo</td>\\n    </tr>\\n    <tr>\\n      <th>22</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs leading to dose interruption of abiraterone</td>\\n    </tr>\\n    <tr>\\n      <th>23</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs leading to dose reduction of capivasertib/placebo</td>\\n    </tr>\\n    <tr>\\n      <th>24</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>AEs of special interest</td>\\n    </tr>\\n    <tr>\\n      <th>25</th>\\n      <td></td>\\n      <td></td>\\n      <td></td>\\n      <td>Other significant AEs</td>\\n    </tr>\\n    <tr>\\n      <th>26</th>\\n      <td></td>\\n      <td>\u2022</td>\\n      <td>Vital signs parameters include systolic and diastolic blood pressure, pulse, body temperature and weight.</td>\\n      <td>Vital signs parameters include systolic and diastolic blood pressure, pulse, body temperature and weight.</td>\\n    </tr>\\n    <tr>\\n      <th>27</th>\\n      <td></td>\\n      <td>\u2022</td>\\n      <td>Assessments cover:  Observed value  Absolute and change from baseline values over time.</td>\\n      <td>Assessments cover:  Observed value  Absolute and change from baseline values over time.</td>\\n    </tr>\\n  </tbody>\\n</table>",
        "TableIndex": "5",
        "TableName": "",
        "Header": []
      },
      "{'IsBold': False, 'font_size': 20, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      205.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "<a href=\"https://google.co.in\"><text>Google India external link</text></a> is given here",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      206.0
    ],
    [
      2.0,
      "Synopsis",
      "text",
      "<a href=\"don\u2019t know what to give here\"><text>Internal link in the same document</text></a> is given here",
      "{'IsBold': False, 'font_size': -1, 'font_style': ''}",
      "Protocol Summary",
      "Synopsis",
      1.1,
      2,
      206.0
    ]
  ]
}
